Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 19;25(18):10051.
doi: 10.3390/ijms251810051.

Molecular Therapeutics for Diabetic Kidney Disease: An Update

Affiliations
Review

Molecular Therapeutics for Diabetic Kidney Disease: An Update

Man Guo et al. Int J Mol Sci. .

Abstract

Diabetic kidney disease (DKD) is a common microvascular complication of diabetes mellitus (DM). With the increasing prevalence of DM worldwide, the incidence of DKD remains high. If DKD is not well controlled, it can develop into chronic kidney disease or end-stage renal disease (ESRD), which places considerable economic pressure on society. Traditional therapies, including glycemic control, blood pressure control, blood lipid control, the use of renin-angiotensin system blockers and novel drugs, such as sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor inhibitors and glucagon-like peptide-1 receptor agonists, have been used in DKD patients. Although the above treatment strategies can delay the progression of DKD, most DKD patients still ultimately progress to ESRD. Therefore, new and multimodal treatment methods need to be explored. In recent years, researchers have continuously developed new treatment methods and targets to delay the progression of DKD, including miRNA therapy, stem cell therapy, gene therapy, gut microbiota-targeted therapy and lifestyle intervention. These new molecular therapy methods constitute opportunities to better understand and treat DKD. In this review, we summarize the progress of molecular therapeutics for DKD, leading to new treatment strategies.

Keywords: diabetic kidney disease; gene therapy; gut microbiota; miRNA; stem cell; therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Current and potential targets for therapeutic interventions of DKD. Abbreviations: RAS: renin–angiotensin–aldosterone system; MRAs: mineralocorticoid system; SGLT2: sodium–glucose cotransporter 2; GLP-1R: glucagon-like peptide 1 receptor; JAK/STAT: Janus kinase/signal transducer and activator of transcription; NOX: nicotinamide adenine dinucleotide phosphate oxidases; AGE: advanced glycation end product; Nrf2: nuclear factor erythroid 2-related factor 2; IPSC: induced pluripotent stem cells; ESC: embryonic stem cell; FMT: fecal microbiota transplantation.

References

    1. Yuan C.M., Nee R., Ceckowski K.A., Knight K.R., Abbott K.C. Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center. Clin. Kidney J. 2017;10:257–262. doi: 10.1093/ckj/sfw112. - DOI - PMC - PubMed
    1. Fried L.F., Folkerts K., Smeta B., Bowrin K.D., Mernagh P., Millier A., Kovesdy C.P. Targeted literature review of the burden of illness in patients with chronic kidney disease and type 2 diabetes. Am. J. Manag. Care. 2021;27:S168–S177. doi: 10.37765/ajmc.2021.88660. - DOI - PubMed
    1. Alicic R.Z., Rooney M.T., Tuttle K.R. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin. J. Am. Soc. Nephrol. 2017;12:2032–2045. doi: 10.2215/CJN.11491116. - DOI - PMC - PubMed
    1. Tuttle K.R., Agarwal R., Alpers C.E., Bakris G.L., Brosius F.C., Kolkhof P., Uribarri J. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022;102:248–260. doi: 10.1016/j.kint.2022.05.012. - DOI - PubMed
    1. Jager K.J., Kovesdy C., Langham R., Rosenberg M., Jha V., Zoccali C. A single number for advocacy and communication- worldwide more than 850 million individuals have kidney diseases. Nephrol. Dial. Transplant. 2019;34:1803–1805. doi: 10.1093/ndt/gfz174. - DOI - PubMed

MeSH terms

LinkOut - more resources